Inicio・Lista de Acciones・TG Therapeutics Inc

TG Therapeutics Inc

Cerrado

SectorSanidad

49.36 -0.82

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

49.29

Máximo

50.48

Métricas clave
By Trading Economics
Ingresos	-3.3M 20M
Ventas	12M 205M
P/B Media del Sector	16.143 68.51
BPA	0.05
Margen de beneficios	9.651
Empleados	399
EBITDA	-24M 28M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+28.59% upside

Dividendos
By Acuity
Próximas Ganancias	2 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.6B 7.1B
Apertura anterior	50.18
Cierre anterior	49.36

Noticias sobre sentimiento de mercado

By Acuity

22%

78%

56 / 340 Clasificación en Healthcare

TG Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 ago 2026, 19:56 UTC

Social Media

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.

4 ago 2026, 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

3 ago 2026, 23:06 UTC

Social Media

TG Therapeutics Inc. shares are higher in after-market trading following Q2 revenues of $236 million and ongoing positive sentiment from clinical trials.

31 jul 2026, 23:16 UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

30 jul 2026, 23:56 UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

29 jul 2026, 15:52 UTC

Social Media

News

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

28 jul 2026, 19:56 UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

27 jul 2026, 19:07 UTC

Social Media

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

24 jul 2026, 23:21 UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

23 jul 2026, 23:22 UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

22 jul 2026, 23:31 UTC

TG Therapeutics Inc shares declined in after-market trading, reflecting a shift toward the lower end of its one-month trading range amid broader market pressures.

21 jul 2026, 22:21 UTC

TG Therapeutics shares are higher in after-market trading, tracking broader market gains following positive earnings from General Motors and 3M.

20 jul 2026, 23:22 UTC

TG Therapeutics shares are higher in after-market trading, recovering from a prior dip despite broader market pressures and four consecutive sessions of declines.

Comparación entre iguales

Cambio de precio

TG Therapeutics Inc previsión

Precio Objetivo

By TipRanks

28.59% repunte

Estimación a 12 Meses

Media 64.14 USD 28.59%

Máximo 86 USD

Mínimo 21 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para TG Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para TG Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

56 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.